Celcuity Skyrocketed 188.67%—What’s Next for a Stock That Tripled in One Day?

Summary
• Celcuity (CELC) surged 188.67% intraday, trading at $39.75 from $13.77
• Phase 3 VIKTORIA-1 trial showed 76% risk reduction in disease progression for gedatolisib triplet
• CEO Brian Sullivan hailed results as 'practice-changing' for HR+/HER2- breast cancer
Celcuity’s stock has erupted following historic Phase 3 trial data, with shares trading at a 210% premium to pre-market levels. The biotech’s breakthrough in advanced breast cancer treatment has triggered a frenzy, with the stock hitting a 52-week high of $46.42 and a low of $35.00. The move underscores the market’s hunger for oncology innovation and Celcuity’s potential to redefine therapeutic standards.

Phase 3 Trial Triumph Sparks 188% Surge
Celcuity’s meteoric rise stems from the VIKTORIA-1 trial’s topline results, where gedatolisib combinations demonstrated unprecedented efficacy. The triplet regimen (gedatolisib + palbociclib + fulvestrant) cut progression/death risk by 76% versus fulvestrant alone, with a 7.3-month median PFS extension. The doublet (gedatolisib + fulvestrant) delivered a 67% risk reduction and 5.4-month PFS boost. These results, coupled with a favorable safety profile and plans for an FDA NDA in Q4 2025, have redefined expectations for HR+/HER2- breast cancer treatment, fueling speculative and institutional buying.

Navigating the Volatility: ETFs and Options for the Upcoming Move
• MACD: 0.459 (bullish), Signal Line: 0.495 (bearish), Histogram: -0.035 (divergence)
• RSI: 63.19 (neutral), Bollinger Bands: $12.68–$14.40 (contraction)
• 200D MA: $12.21 (far below current price), Kline Pattern: Short-term bearish
Celcuity’s technicals suggest a volatile, overbought short-term trend with a long-term consolidation pattern. The stock’s 188.67% surge has pushed it well above its 200-day average, but the bearish Kline pattern warns of potential pullbacks. With no options data available, traders should focus on key levels: support at $35.00 (intraday low) and resistance at $46.42 (52-week high). A bullish breakout above $46.42 could trigger a retest of $50.00, while a breakdown to $30.00 would signal a return to mean reversion. Aggressive bulls may consider scaling into long positions near $35.00, while hedgers should cap risk with tight stop-losses.

Backtest Celcuity Stock Performance
The 3-Day win rate for CELC after an intraday increase of more than 189% is 41.12%, the 10-Day win rate is 40.10%, and the 30-Day win rate is 37.56%. The maximum return during the backtest was 15.44%, with a maximum return day of 58.

Act Now: Ride the Biotech Breakthrough Wave
Celcuity’s VIKTORIA-1 data has ignited a paradigm shift in oncology, with the stock poised to either consolidate gains or extend its rally toward $50.00. The FDA NDA filing in Q4 2025 and topline data for the PIK3CA mutation cohort by year-end will be critical catalysts. Meanwhile, sector leader Amgen (AMGN) slipped -1.01% today, highlighting Celcuity’s sector outperformance. Investors should prioritize monitoring the $46.42 resistance and $35.00 support levels, while keeping an eye on regulatory developments. For now, the biotech’s blockbuster potential warrants a bullish stance—provided the $35.00 support holds.